|

Pucotenlimab Clinical Trials

6 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 4Phase 1/2: 2

Top Sponsors

  • Sun Yat-sen University2
  • Zhejiang Provincial People's Hospital1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Ji Dongmei1
  • Groupe Oncologie Radiotherapie Tete et Cou1

Indications

  • Cancer6
  • Salivary Gland Carcinomas1
  • Proterizumab1
  • LDRT1
  • Locally Advanced Head and Neck Squamous Cell Carcinoma1

Other6 trials

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Phase 2
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Phase 1/2
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Phase 1/2
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
Phase 2
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.